- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04945395
Effect of Functional Electric Stimulation for Recovery of Dorsiflexion After Stroke
The Effect of Using Functional Electric Stimulation for the Recovery of Dorsiflexion During Rehabilitation of Gait Function, in the Subacute Phase After Stroke- a Randomized Controlled Exploratory Study
The purpose of this project is to investigate the effect of functional electrical stimulation (FES) for recovery of dorsiflexion after stroke. It will be led from the University Department of Rehabilitation Medicine at Danderyd Hospital (RMDS) in collaboration with the MoveAbility Lab at KTH Royal Institute of Technology. Patients referred to RMDS for inpatient rehabilitation early after hemiparetic stroke will be included.
The overall aim is to explore how 4 weeks of training incorporating the FES-system (L300 Go System ® Bioness, Ottobock) effect function of the lower extremity, gait function and mobility when compared to conventional training only, in the subacute stage after stroke.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will be included and allocated to either experimental group with training incorporating the FES-system and conventional training or to control group with conventional training only. Data will be collected before and after the intervention at RMDS and at the MoveAbility Lab. Physical tests and self-scored questionnaires of self-perceived aspects of functioning and disability will be performed at RMDS and gait analysis with 3D cameras and assessment of muscle function with EMG will be performed at the MoveAbilityLab. In addition, a short assessment of body function and activity will be performed weekly at RMDS by the therapist responsible for the rehabilitation intervention.
The experimental group will wear the FES-system L300 Go at all times when the patient is taking part in rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist. The settings will be adjusted by the employee from the technical company and/or the physiotherapist continuously during the intervention if needed. The system will register the distance and time accomplished during each session. Due to risk of skin irritation, if the system is overused in the beginning the experimental group will have access to an ankle-foot-orthosis too.
The control group will wear an ankle-foot-orthosis (AFO) and receive conventional training. The control group will wear a FES-system too, to record the distance and time accomplished during each session, but the system will not be active for stimulation.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Susanne Palmcrantz, PhD
- Phone Number: 004681235000
- Email: susanne.palmcrantz@ki.se
Study Locations
-
-
Stockholm
-
Danderyd, Stockholm, Sweden, 18288
- Recruiting
- Department of Rehabilitation Medicine, Danderyd Hospital
-
Contact:
- Susanne Palmcrantz, PhD
- Email: susanne.palmcrantz@ki.se
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligible will be patients who have suffered a stroke, verified by CT or MRI examination and are admitted to inpatient care at the University Department of Rehabilitation Medicine Stockholm, Danderyd Hospital in Sweden where approximately 220 patients are treated annually (Stroke (50%)).
Inclusion criteria:
- 20 participants with hemiplegia
- Dependence in ambulation (0- 4 according to the Functional Ambulation Categories)
- >= 50 points on the Trunc Control Test.
- Impaired dorsiflexion manifested as impaired voluntarily dorsiflex and to hold the ankle in a dorsiflexed position while sitting and for ambulatory participants: during swing phase and heel strike while walking as demonstrated by visual inspection during gait analysis performed by the physiotherapist.
- Recommended to be fitted with an ankle-foot orthosis (AFO) by an experienced physiotherapist.
- Able to understand study information and to give informed consent.
Exclusion Criteria:
- Contracture severely restricting gait movements at any lower limb joint
- Cardiovascular or other somatic condition incompatible with intensive gait training
- Notifiable infectious disease, contagious infections (e.g. Methicillin Resistant Staphylococcus Aureus (MRSA) or Extended Spectrum Beta Lactamase bacteria (ESBL)). - Not able to participate in the rehabilitation intervention due to behavioral disorder or psychiatric disease.
- The FES-system L300 Go ® should not be used if a the patient has a pacemaker, defibrillator or any electrical implant, a metallic implant in the affected leg, a cancerous lesion in the affected leg, a fracture or dislocation in the affected leg or if the affected leg is swollen, infected, or has inflamed areas or skin eruptions, such as phlebitis, thrombophlebitis, and varicose veins in the affected leg or if the patient is pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: FES and conventional training
The experimental group will wear the Functional electrical stimulation system L3100 Go for dorsiflexion of the ankle during conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
|
The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke.
Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
|
ACTIVE_COMPARATOR: AFO and Conventional training only
The control group will wear an ankle-foot-orthosis (AFO) to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions involving the lower extremity led or instructed by a physiotherapist.
|
The control group will be fitted with an ankle-foot-orthosis (AFO) according to clinical practice to enhance dorsiflexion of the foot while taking part in conventional rehabilitation interventions during 4 weeks of inpatient rehabilitation including walking and mobility training in the subacute phase after hemiplegic stroke
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gait Profile Score (GPS)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
GPS is a single index measure that summarises the overall deviation of kinematic gait data relative to normative data.
The GPS can be decomposed to provide the Gait Variable Score (GVS) (an index that measures single gait variable deviation), for nine key relevant kinematic variables.
A larger GPS indicates greater deviation from normal gait
|
At baseline and after completion of the 4 week intervention to assess change.
|
Ankle Sagittal range (degrees)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses range of motion in the ankle (plantarflexion from 0-50 degrees, dorsiflexion from 0-20 degrees)
|
At baseline and after completion of the 4 week intervention to assess change.
|
Ankle Positive work
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses the force at the ankle joint (J/kg) detected in gait laboratory
|
At baseline and after completion of the 4 week intervention to assess change.
|
Step length
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Step length will be assessed in the gait laboratory with 3D gait analyses
|
At baseline and after completion of the 4 week intervention to assess change.
|
6 minutes walk test
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses walking endurance in meters walked
|
At baseline and after completion of the 4 week intervention to assess change.
|
Rated Perceived Exertion (RPE) Scale
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Ratings (min 6, max 20) according to the RPE scale are made at the end of the 6 minutes walk test.
A higher score indicates a higher degree of perceived exertion.
|
At baseline and after completion of the 4 week intervention to assess change.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Montreal Cognitive Assessment (MoCa)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses mental function (0p max impairment summed up to 30p no detected impairment)
|
At baseline and after completion of the 4 week intervention to assess change.
|
Fugl-Meyer score (FMA-LE)
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Assesses sensory and movement related functions in the lower extremity (0p max impairment summed up to 86p max no detected impairment)
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Neuroflexor
Time Frame: At baseline, weekly during the intervention, and after completion of the 4 week intervention to assess change.
|
Medical technology device.
Assesses spasticity by identifying the neural, viscous and elastic components during passive movement using a biomechanical algorithm (presented in Newton)
|
At baseline, weekly during the intervention, and after completion of the 4 week intervention to assess change.
|
Modified Ashworth scale 0-5
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention, to assess change.
|
Assesses spasticity on a 6 point scale/muscle (0p no impairment, 5p max impairment/muscle)
|
At baseline, weekly during the intervention and after completion of the 4 week intervention, to assess change.
|
Passive range of motion in the lower extremity
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Clinical assessment of range of motion with a goniometer
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Medical Research Council scale
Time Frame: At baseline and after completion of the 4 week intervention
|
Assesses muscle strength on a 6 point scale/muscle (0p max impairment summed up to 5p no impairment/muscle)
|
At baseline and after completion of the 4 week intervention
|
The Balance evaluation systems test (BEST-test)
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Assesses postural control, incorporating bio-mechanical systems, limits of stability, anticipatory postural adjustment, automatic postural responses, sensory orientation, stability in gait (0p max impairment summed up to 108p no impairment)
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
The 10 meter walk test
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Assesses gait speed
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
6 minutes walk test
Time Frame: At baseline, weekly during the intervention and after the intervention to assess change
|
Assesses walking endurance in meters walked
|
At baseline, weekly during the intervention and after the intervention to assess change
|
Rated Perceived Exertion (RPE) Scale
Time Frame: At baseline, weekly during the intervention and after the intervention to assess change
|
Ratings (min 6, max 20) according to the RPE scale are made at the end of the 6 minutes walk test.
|
At baseline, weekly during the intervention and after the intervention to assess change
|
Indirect Calorimetries
Time Frame: At baseline and after the intervention to assess change
|
To assess energy expenditure based on respiratory gas exchange.
Will be performed during the 6 minutes walk test.
|
At baseline and after the intervention to assess change
|
Electromyography (EMG)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
EMG is used to measure muscle activation patterns during gait.
|
At baseline and after completion of the 4 week intervention to assess change.
|
Walking impact scale (MSWS-12 S)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses self-perceived limitations in walking (12p no impairments summed up to 60p max impairment)
|
At baseline and after completion of the 4 week intervention to assess change.
|
The Functional Ambulation Categories (FAC)
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Assesses independence in walking (0p nonfunctional, 5p independent) Total score 0-5p
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Falls Efficacy Scale (FES-S)
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses self perceived balance in every day life activities rated on a 11 point scale (0p not safe at all 10p completely safe).
Total score: 0- 130 p
|
At baseline and after completion of the 4 week intervention to assess change.
|
Barthel Index
Time Frame: At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Assesses independence in mobility and personal care (0p dependent 10/15p independent) Total score 0-100p
|
At baseline, weekly during the intervention and after completion of the 4 week intervention to assess change.
|
Eq-5d-5l
Time Frame: At baseline and after completion of the 4 week intervention to assess change.
|
Assesses self perceived health related quality of life in five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and on a vertical visual analogue scale.
Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Responses are coded as single-digit numbers expressing the severity level selected in each dimension (1 = no problem, 5 = extreme problems).
The vertical visual analogue scale is graded from 0-100 (0 = the worst health you can imagine 100 = the best health you can imagine).
|
At baseline and after completion of the 4 week intervention to assess change.
|
A study specific questionnaire - a questionnaire for the experimental group
Time Frame: After completion of the 4 week intervention
|
A questionnaire with 11 questions assessing the patients experience of participating in the study and the use of the FES-system.
The patient rates on a 10 graded scale (0 = not at all, 10 = very much): the information given about the study, the experience, usability and comfort of using the system, eventual pain, skin problems and technical problems with the system and experience of eventual benefits from having used the system.
|
After completion of the 4 week intervention
|
Distance accomplished during each training session
Time Frame: Daily during the intervention
|
The FES-system will collect this data to assess training intensity
|
Daily during the intervention
|
Time accomplished during each training session
Time Frame: Daily during the intervention
|
The FES-system will collect this data to assess training intensity
|
Daily during the intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susanne Palmcrantz, PhD, Dep of Clinical Sciences, Karolinska Institutet
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FES-study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on FES and Conventional training
-
University Hospital of FerraraCompletedStroke | Arm Motor RecoveryItaly
-
University Health Network, TorontoUniversity of Alberta; Heart and Stroke Foundation of CanadaCompleted
-
Shirley Ryan AbilityLabEnrolling by invitation
-
University of Sao Paulo General HospitalAgência Brasileira de Desenvolvimento Industrial (Brazilian Agency For Industrial...Not yet recruitingBrain Injuries | Spinal Cord Injuries | Muscle AtrophyBrazil
-
Ontario Neurotrauma FoundationUnknown
-
Spaulding Rehabilitation HospitalThe Craig H. Neilsen FoundationCompletedSpinal Cord InjuriesUnited States
-
Toronto Rehabilitation InstituteRick Hansen FoundationCompleted
-
Shirley Ryan AbilityLabU.S. Department of EducationActive, not recruiting
-
Stichting ReadeEnrolling by invitationSpinal Cord InjuriesNetherlands
-
US Department of Veterans AffairsWithdrawn